Ashi Ramavat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashi Ramavat has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Baby Kataria
SRM University, Sonīpat, India, India
2 shared publications - Priya Antil
Department of Biotechnology, Deenbandhu Chhotu Ram University of Science and Technology (DCRUST), Sonepat 131001, Haryana, India
2 shared publications - Ramendra Pati Pandey
School of Biosciences and Bioengineering, D Y Patil International University, Akurdi, Pune, India
2 shared publications - Soniya Kaushik
Department of Biotechnology, SRM University, Delhi-NCR, Sonepat 131029, Haryana, India
2 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11941
Nanomedicine for Cancer and Autoimmune Immunotherapy
Nanomedicine has now become a transformative platform that enhances the precision and efficacy of immunotherapy approaches and allows customizations like never before when it comes to cancer, as well as autoimmune conditions. Using platforms based on nanoscale, researchers have been able to manipulate immune responses operating across spatial and temporal scales to address key limitations of conventional immunotherapy associated with working with immune response such as immune evasion, systemic toxicity, and poor pharmacokinetics. Sophisticated nanoparticles (such as stimuli-sensitive ones, exosome-mimetic vesicle nanoparticles, and nanoparticles with CRISPR) allow directed immunomodulators, antigens, and gene-editing systems to reach one or more particular immune compartments. The innovations allow reprogramming of immune cells, immune tolerance rejuvenation, and expansion of antitumor immunity without significant off-target effects. Finding applications in integrating the artificial intelligence as well as multi-omics techniques, the process leads to personalization of the nano-immunotherapies based on patient-specific immuno-signatures. The chapter discusses the mechanistic rationale, therapeutic advancement, and the translational opportunities of nanotechnology-based immunotherapies that define them as part of a foundation of future generations of clinical approaches to precision immune modulation in oncology and autoimmune diseases.
- 11 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11941
Open AccessNanomedicine for Cancer and Autoimmune Immunotherapy
Nanomedicine has now become a transformative platform that enhances the precision and efficacy of immunotherapy approaches and allows customizations like never before when it comes to cancer, as well as autoimmune conditions. Using platforms based on nanoscale, researchers have been able to manipulate immune responses operating across spatial and temporal scales to address key limitations of conventional immunotherapy associated with working with immune response such as immune evasion, systemic toxicity, and poor pharmacokinetics. Sophisticated nanoparticles (such as stimuli-sensitive ones, exosome-mimetic vesicle nanoparticles, and nanoparticles with CRISPR) allow directed immunomodulators, antigens, and gene-editing systems to reach one or more particular immune compartments. The innovations allow reprogramming of immune cells, immune tolerance rejuvenation, and expansion of antitumor immunity without significant off-target effects. Finding applications in integrating the artificial intelligence as well as multi-omics techniques, the process leads to personalization of the nano-immunotherapies based on patient-specific immuno-signatures. The chapter discusses the mechanistic rationale, therapeutic advancement, and the translational opportunities of nanotechnology-based immunotherapies that define them as part of a foundation of future generations of clinical approaches to precision immune modulation in oncology and autoimmune diseases.
- Open Access
- 14 October 2025
- Published by MDPI AG in Preprints.org
Nanomedicine for Cancer and Autoimmune Immunotherapy
Nanomedicine has now become a radical agent of change in the game of immunotherapy and introduced precision, control, and customization like never before when it comes to cancer, as well as autoimmune conditions. Using platforms based on nano scale, researchers have been able to manipulate immune responses by working on a scale both spatial and temporal in such a way that it helps overcome the drawbacks associated with working with immune response such as immune evasion, systemic toxicity and poor pharmacokinetics. Sophisticated nanoparticles (such as stimuli-sensitive ones, exosome-mimetic vesicle nanoparticles, and nanoparticles with CRISPR) allow directed immunomodulators, antigens and gene-editing systems to reach one or more particular immune compartments. The innovations allow reprogramming of immune cells, immune tolerance rejuvenation and expansion of antitumor immunity without significant off-target effects. Finding applications in integrating the artificial intelligence as well as multi-omics techniques, the process leads to personalization of the nano-immunotherapies based on patient-specific immuno-signatures. The chapter discusses the mechanistic rationale, therapeutic advancement, and the translational opportunities of nanotechnology-based immunotherapies that define them as part of a foundation of future generations of clinical approaches to precision immune modulation in oncology and autoimmune diseases.
- 14 October 2025
- Published by MDPI AG in Preprints.org
Open AccessNanomedicine for Cancer and Autoimmune Immunotherapy
Nanomedicine has now become a radical agent of change in the game of immunotherapy and introduced precision, control, and customization like never before when it comes to cancer, as well as autoimmune conditions. Using platforms based on nano scale, researchers have been able to manipulate immune responses by working on a scale both spatial and temporal in such a way that it helps overcome the drawbacks associated with working with immune response such as immune evasion, systemic toxicity and poor pharmacokinetics. Sophisticated nanoparticles (such as stimuli-sensitive ones, exosome-mimetic vesicle nanoparticles, and nanoparticles with CRISPR) allow directed immunomodulators, antigens and gene-editing systems to reach one or more particular immune compartments. The innovations allow reprogramming of immune cells, immune tolerance rejuvenation and expansion of antitumor immunity without significant off-target effects. Finding applications in integrating the artificial intelligence as well as multi-omics techniques, the process leads to personalization of the nano-immunotherapies based on patient-specific immuno-signatures. The chapter discusses the mechanistic rationale, therapeutic advancement, and the translational opportunities of nanotechnology-based immunotherapies that define them as part of a foundation of future generations of clinical approaches to precision immune modulation in oncology and autoimmune diseases.